Toripalimab (Tuoyi™) is a selective, recombinant, humanized monoclonal antibody against
programmed death protein 1 (PD-1) developed by Shanghai Junshi Bioscience Co., Ltd …

Hepatocellular carcinoma remains a global health challenge affecting close to 1 million
cases yearly. Liver transplantation provides the best long‐term outcomes for those meeting …

Background Over 70% of the patients with hepatocellular carcinoma (HCC) are diagnosed
at an advanced stage and lose the opportunity for radical surgery. Combination therapy of …

The incidence rate of hepatocellular carcinoma (HCC) is expected to increase, with most
cases occurring in Asia. In some parts of Asia, the occurrence of HCC developing from …

Despite advances in cancer treatment, hepatocellular carcinoma (HCC), the most common
form of liver cancer, remains a major public health problem worldwide. The immune …

Significance: Hepatocellular carcinoma (HCC) is a liver malignancy with high mortality rate,
limited treatment options, and poor prognosis. Sorafenib has been the only systemic …

Curative surgery and locoregional therapy are radical therapies for patients with HCC. But
more than 80% of HCC patients cannot be fitful for radical therapies because of local …

Background Hepatocellular carcinoma (HCC) is one of the cancers with the highest
morbidity and mortality. Sorafenib used to be the main treatment for unresectable HCC …

Background The most effective treatment with immune checkpoint inhibitors (ICIs) is limited
to the microsatellite instability high (MSI-H) subgroup of advanced colorectal cancer. ICIs are …

Surgical resection and liver transplant remain the only curative therapies for most patients
with hepatocellular carcinoma (HCC). Systemic therapy options have typically been …